| Ticker |
TXG
|
| CIK | 0001770787 |
| SIC | 3826 |
| Sector | Manufacturing |
| Industry Category | Measuring And Control Equipment |
| Industry Group | Lab Analytical Instruments |
| Address | 6230 STONERIDGE MALL ROAD, PLEASANTON, CA, 94588 |
| Website | 10xgenomics.com |
| Phone | (925) 401-7300 |
| CEO | Serge Saxonov |
| Employees | 1,240 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Zacks.com featured highlights include Tsakos Energy Navigation Limited, 10x Genomics, Pan American Silver, Wolverine World Wide and InterfaceTsakos Energy Navigation, 10x Genomics, Pan American Silver, Wolverine World Wide, and Interface rank high on efficiency metrics, signaling strong profit potential in volatile markets. TXG Q2 Deep Dive: Robust Product Demand and Cautious Outlook Amid Funding UncertaintyBiotech company 10x Genomics (NASDAQ:TXG) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 12.9% year on year to $172.9 million. On the other hand, next quarter’s revenue guidance of $142 million was less impressive, coming in 1.5% below analysts’ estimates. Its non-GAAP profit of $0.48 per share was significantly above analysts’ consensus estimates. 5 Must-Buy Efficient Stocks to Buy Amid Volatile Market ConditionsTsakos Energy Navigation, 10x Genomics, Pan American Silver, Wolverine World Wide, and Interface top an efficiency-driven stock screen. Why 10x Genomics (TXG) Stock Is Falling TodayShares of biotech company 10x Genomics (NASDAQ:TXG) fell 5.5% in the morning session after the company reported strong second-quarter results that surpassed Wall Street's expectations for both revenue and profitability. The company announced revenue of $172.9 million, a 12.9% increase from the prior year and a significant 24% above analyst estimates. Profitability was a major bright spot, with GAAP earnings per share of $0.28, crushing the consensus forecast of a $0.37 loss per share. This impre 10x Genomics (NASDAQ:TXG) Reports Upbeat Q2, Stock SoarsBiotech company 10x Genomics (NASDAQ:TXG) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 12.9% year on year to $172.9 million. On the other hand, next quarter’s revenue guidance of $142 million was less impressive, coming in 1.5% below analysts’ estimates. Its GAAP profit of $0.28 per share was significantly above analysts’ consensus estimates. |
